Get the Stockscreener App
208.38
0.29%
-0.61
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $208.38, with a volume of 8.98M.
It is down -0.29% in the last 24 hours and down -5.18% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$208.99
Open:
$209.66
24h Volume:
8.98M
Relative Volume:
1.27
Market Cap:
$368.57B
Revenue:
$61.16B
Net Income/Loss:
$4.19B
P/E Ratio:
88.24
EPS:
2.3614
Net Cash Flow:
$17.82B
1W Performance:
+0.21%
1M Performance:
-5.18%
6M Performance:
-9.23%
1Y Performance:
+20.46%
1-Day Range:
$207.82
$212.35
1-Week Range:
$203.01
$212.35
52-Week Range:
$168.54
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
208.38 | 368.57B | 61.16B | 4.19B | 17.82B | 2.3614 |
LLY
Lilly Eli Co
|
927.03 | 828.17B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
234.18 | 564.05B | 96.36B | 21.04B | 19.70B | 8.6488 |
AZN
Astrazeneca Plc
|
204.80 | 317.61B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
119.07 | 294.09B | 64.93B | 18.26B | 12.36B | 7.2751 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Asset Management One Co. Ltd. Has $209.74 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. (NYSE:ABBV) Short Interest Update - MarketBeat
AbbVie Inc. (ABBV): A Bull Case Theory - MSN
Top Analyst Reports for Microsoft, AbbVie & BHP - Yahoo Finance
The Psychedelic Revolution in Mental Healthcare - The Motley Fool
Should you buy AbbVie stock before April 29? - MSN
AbbVie inks $745 million deal to develop pain medicines from Chinese drugmaker - Crain's Chicago Business
AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the Stock - The Globe and Mail
AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit - Yahoo Finance
Merit Financial Group LLC Has $21.32 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Pertzye Market Booming with Rapid Growth Through 2033| AbbVie • Nestlé Health Science • Solvay Pharmaceuticals - openPR.com
AE Wealth Management LLC Purchases 7,696 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie, Inc. Trade Ideas — TURQUOISE:4ABD - TradingView — Track All Markets
Why AbbVie Is a No-Brainer Stock to Buy on the Dip - AOL.com
AbbVie Steps Deeper Into Obesity Market With New Phase 1 ABBV-295 Trial - TipRanks
AbbVie’s Head-to-Head Psoriasis Study Sets Up New Catalyst for ABBV Investors - TipRanks
ABBV: Abbott Laboratories Reports In-Line EPS and Strong Revenue Beat - GuruFocus
ABBV Stock Quote Price and Forecast - CNN
Nations Financial Group Inc. IA ADV Has $4.88 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
Lbp Am Sa Purchases 8,678 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie eases the pain with $745m licensing deal - BioXconomy
Cwm LLC Boosts Holdings in AbbVie Inc. $ABBV - MarketBeat
Diversified Management Inc. Takes Position in AbbVie Inc. $ABBV - MarketBeat
Adelphi Trust Co Makes New Investment in AbbVie Inc. $ABBV - MarketBeat
Operating expenses (excl. COGS) of AbbVie, Inc. – BSESOF:4AB - TradingView — Track All Markets
Evercore ISI Tweaks AbbVie (ABBV) Estimates, Lowers Price Target Marginally - Yahoo Finance
Spectrum Asset Management Reduces AbbVie Stake - National Today
NSCLC Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | AbbVie, AstraZeneca and Daiichi Sankyo, Shanghai Henlius Biotech, Moderna Therapeutics/ Merck, BeyondSpring, Cullinan - Barchart.com
RemeGen (09995.HK) Receives USD650M Upfront Payment from AbbVie for RC148 - AASTOCKS.com
AbbVie Inc. $ABBV Shares Purchased by Farther Finance Advisors LLC - MarketBeat
Bingham Private Wealth LLC Purchases Shares of 5,019 AbbVie Inc. $ABBV - MarketBeat
Franklin Income Focus ETF's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie Inc.: - marketscreener.com
AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance Singapore
AbbVie Inc. stock (US00287Y1091): Is its immunology dominance strong enough to unlock new upside? - AD HOC NEWS
AbbVie (NYSE:ABBV) Shares Up 1.9%Should You Buy? - MarketBeat
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
BRAF Mutated Non-small Cell Lung Cancer Market: Rapid Increment Driven by Innovation by 2036 – DelveInsight | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics - Barchart.com
Abbvie nabs two Nav1.8 pain projects from Haisco in $745M deal - BioWorld News
Could AbbVie Crash Lilly's Weight‑Loss Party? - The Globe and Mail
AbbVie Inc. stock (US00287Y1091): Is immunology dominance strong enough to unlock new upside? - AD HOC NEWS
ABBV stock shows mixed momentum on neutral MACD reading: weekly review - Traders Union
Natural Investments Trims Stake in AbbVie - National Today
JM2 Capital Inc. Buys Shares of 2,519 AbbVie Inc. - National Today
Erin Lichy Gets Real About Her Natrelle® Breast Augmentation - AbbVie News Center
Erin Lichy shares her breast augmentation story in Natrelle campaign - Stock Titan
Natural Investments LLC Decreases Stake in AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Rede Wealth LLC - MarketBeat
Haisco Pharma strikes deal with AbbVie to develop novel pain medicines - The Pharma Letter
AbbVie Ovarian Cancer Data And Pain Deal Extend Long Term Story - Yahoo Finance
What is behind AbbVie stock's recent drop in value today - Traders Union
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.16%
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):